Pregnancy outcome after early exposure to nivolumab, a PD-1 checkpoint inhibitor for relapsed Hodgkin’s lymphoma

Janine R. Hutsona Department of Obstetrics and Gynecology, Western University, London, Canada

Genevieve Eastabrooka Department of Obstetrics and Gynecology, Western University, London, Canada;b Children’s Health Research Institute, Division of Maternal, Fetal and Newborn Health, London, Canada

Facundo Garcia-Bournissenc Department of Pediatrics, Western University, London, Canada;d Children’s Health Research Institute, Division of Child’s Health and Therapeutics, London, CanadaCorrespondence[email protected]

References

Poulet FM, Wolf JJ, Herzyk DJ, et al. An evaluation of the impact of PD-1 pathway blockade on reproductive safety of therapeutic PD-1 inhibitors. Birth Defects Res B Dev Reprod Toxicol. 2016;107(2):108–119.
PubMedGoogle Scholar
Bristol-Myers Squibb Canada Co. OPDIVO (nivolumab) product monograph. [cited 2021 Apr 15]. Available from: https://www.bms.com/assets/bms/ca/documents/productmonograph/OPDIVO_EN_PM.pdf
Google Scholar
Xu W, Moor RJ, Walpole ET, et al. Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature. Melanoma Res. 2019;29(3):333–337.
PubMed Web of Science ®Google Scholar
Bucheit AD, Hardy JT, Szender JB, et al. Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition. Melanoma Res. 2020;30(4):423–425.
PubMed Web of Science ®Google Scholar
Haiduk J, Ziemer M. Pregnancy in a patient with metastatic uveal melanoma treated with nivolumab. J Dtsch Dermatol Ges. 2021;19:762–765.
Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Pregnancy outcome after early exposure to nivolumab, a PD-1 checkpoint inhibitor for relapsed Hodgkin’s lymphoma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pregnancy outcome after early exposure to nivolumab, a PD-1 checkpoint inhibitor for relapsed Hodgkin’s lymphoma

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date